Background: Hypofunction of N-methyl-D-aspartate (NMDA) subtype glutamate receptor has
been implicated in the pathophysiology of schizophrenia. D-serine is a full agonist of the …

Background The hypofunction of theN-methyl-D-aspartate (NMDA) subtype of glutamate
receptors has been implicated in the pathophysiology of schizophrenia. Several lines of …

BACKGROUND: D-serine is an allosteric modulator of the brain N-methyl-d-aspartate
(NMDA) receptor and a potential novel treatment of schizophrenia. Double-blind studies …

BACKGROUND: D-serine, a selective full agonist at the glycine site of N-methyl-d-aspartate
glutamate receptor, might presently be the compound of choice for counteracting the …

BACKGROUND: Hypofunction of the N-methyl-d-aspartate (NMDA) subtype glutamate
receptor had been implicated in the pathophysiology of schizophrenia. Treatment with D …

OBJECTIVE: d-Serine is a full agonist at the glycine site on the N-methyl-d-aspartate
(NMDA) receptor. Previous administration of d-serine to schizophrenic patients taking …

Several lines of evidence suggest that d-serine, an endogenous agonist of the glycine site
on the NMDA receptors, might play a role in the pathophysiology of schizophrenia. The …

Background: Observations that antagonists of the N-methyl-d-aspartate (NMDA) receptor of
glutamatergic neurons can mimic symptoms of schizophrenia have raised the hope that …

Clinical trials demonstrated that d-serine administration improves schizophrenia symptoms,
raising the possibility that altered levels of endogenous d-serine may contribute to the N …

The potential implication of a decrease in the function of N-methyl-d-aspartate receptors
(NMDARs) in the pathophysiology of schizophrenia has long been hypothesised …